Skip to content
drillr.ai

IONS

Ionis Pharmaceuticals, Inc.

NASDAQ · USHealthcareBiotechnology
$52.95-2.65%

Price as of Jul 20, 2026

IONS news

Ionis Pharmaceuticals, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 20, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ:IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ionis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here f

    ACCESSWIRE ·

  2. Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

    SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders’ rights firm Hagens Berman to open an investigation into whether Ionis

    Globe Newswire ·

  3. Ionis Pharmaceuticals, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Ionis Pharmaceuticals, Inc. (IONS)

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 15, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Ionis Pharmaceuticals, Inc. ("Ionis Pharmaceuticals, Inc.") (NASDAQ:IONS) concerning potential violations of the federal securities laws. Ionis Pharmaceuticals shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. The investiga

    ACCESSWIRE ·

  4. IONS Investor Alert: Levi & Korsinsky Investigates Ionis Pharmaceuticals, Inc. (IONS) for Potential Securities Fraud

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 15, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Ionis Pharmaceuticals, Inc. ("Ionis Pharmaceuticals, Inc.") (NASDAQ:IONS) concerning potential violations of the federal securities laws. Ionis Pharmaceuticals shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. The investiga

    ACCESSWIRE ·

  5. Ionis to hold second quarter 2026 financial results webcast

    Ionis to hold second quarter 2026 financial results webcast Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events (https://cts.businesswire.com/ct/CT?id=smart

    Business Wire ·

  6. IONS SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Ionis Pharmaceuticals, Inc. For Possible Securities Law Violations

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 14, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Ionis Pharmaceuticals, Inc. ("Ionis Pharmaceuticals, Inc.") (NASDAQ:IONS) concerning potential violations of the federal securities laws. Ionis Pharmaceuticals shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. The investiga

    ACCESSWIRE ·

  7. Levi & Korsinsky Notifies Investors of a Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals (IONS)

    Ionis Pharmaceuticals (NASDAQ: IONS) investors absorbed a >20% share decline after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint. Levi & Korsinsky is investigating potential securities law violations. NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Ionis Pharmaceuticals (NASDAQ: IONS) shares dropped more than 20% by midday trading on July 9, 2026, after the Company disclosed that its late-stage CARDIO-TTRansform trial failed to meet its primary endpoint. If you held IONS shares an

    Globe Newswire ·

  8. Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

    Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease - Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing

    Business Wire ·

  9. Levi & Korsinsky Announces Investigation of Securities Claims Against Ionis Pharmaceuticals, Inc. (IONS)

    NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / July 13, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Ionis Pharmaceuticals, Inc. ("Ionis Pharmaceuticals, Inc.") (NASDAQ:IONS) concerning potential violations of the federal securities laws. Ionis Pharmaceuticals shares were falling more than 20% on July 9, 2026, after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. The investiga

    ACCESSWIRE ·

  10. IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)

    IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint -- and now have legal rights worth protecting. Levi & Korsinsky is investigating. Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansfo

    Business Wire ·

  11. IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals

    IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals PR Newswire NEW YORK, July 10, 2026 Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IONS investors. NEW YORK, July 10, 2026 /PRNewswire/ -- Sha

    PR Newswire ·

  12. Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)

    Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS) PR Newswire NEW YORK, July 9, 2026 Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating. NEW YORK, July 9, 2026 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) shares were falling more than 20% on July 9, 2026

    PR Newswire ·

  13. Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

    Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S. - Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments - - Ionis to independently commercialize zilganersen in the U.S. assuming FDA approval - Ionis Pharmaceuticals, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fionis.com%2F&esheet=54559214&newsitemid=20

    Business Wire ·

  14. TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

    TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) – Proven to deliver significant and robust triglyceride reductions – – Only treatment for sHTG indicated to reduce the risk of acute pancreatitis – – Ionis’ first independent commercial launch in a prevalent condition – – Ionis to host webcast today at 3:30 p.m. ET – Ionis Pharmaceuticals, Inc. (https://cts.

    Business Wire ·

  15. Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

    Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B – Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis – – A loss in surface antigen is

    Business Wire ·

  16. Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

    Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease - Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results general

    Business Wire ·

  17. Ionis to host 2026 virtual Annual Meeting of Stockholders

    Ionis to host 2026 virtual Annual Meeting of Stockholders Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: * 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders * All stockholders of record at the close of business on April 7, 2026, are invited to participate

    Business Wire ·

  18. Ionis to present at upcoming investor conferences

    Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: * Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026 * 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 * Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, 2026 A live webcast of these presentations can be

    Business Wire ·

  19. Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

    Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B – Regulatory submission supported by Phase 3 B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B - – Breakthrough Therapy designation added to Fast Track Designation, recognizing potential for substantial improvement over existing trea

    Business Wire ·

  20. Ionis to hold first quarter 2026 financial results webcast

    Ionis to hold first quarter 2026 financial results webcast Webcast scheduled for Wednesday, April 29 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events (https://cts.businesswire.com/ct/CT?id=smart

    Business Wire ·